Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
in portfolio news
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Dieter Weinand as Chairman of the Board of Directors and the new appointment of Paolo Pucci to the Board of Directors, effective immediately. Mr. Weinand succeeds Philip Astley-Sparke who in January transitioned from part time Executive Chairman to full time Chief Executive Officer.
“We are pleased to announce these changes to our Board. Dieter has served on the Replimune Board since June 2018 and I am delighted he has agreed to step up to the Chairman role following my appointment as Chief Executive Officer,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Both Dieter and Paolo bring to Replimune vast international experience within commercial, operational, and strategic functions in the pharmaceutical industry with strong and relevant profiles as we progress our products towards the market. Paolo has extensive experience in the field of oncology while at Bayer and, more recently, at the helm of ArQule Inc., a Nasdaq-listed oncology and rare diseases company that was sold to Merck for approximately $2.7 billion in January 2020.”
Mr. Dieter Weinand was formally the Executive Vice President of Primary Care and a member of the Executive Committee at Sanofi since November 1, 2018. Before moving to Sanofi, Mr. Weinand was the President of The Pharmaceuticals Division and member of the Management Board at Bayer AG. Prior to his work at Sanofi and Bayer, Mr. Weinand has held various positions in commercial, operational and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb and Otsuka. Mr. Weinand earned an MS in Pharmacology and Toxicology from Long Island University, New York, and a BA in biology from Concordia College, New York. Mr. Weinand is a board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), a board member of the European Federation of Pharmaceutical Industries & Associations (EFPIA), a member of the Board of Directors of HealthPrize Technologies.
Mr. Paolo Pucci most recently served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology company engaged in the research and development of targeted therapeutics that was acquired by Merck in January 2020. Prior to joining ArQule in 2008, Mr. Pucci worked at Bayer AG, where he served in a number of leadership capacities including President of the Oncology & Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer AG, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci earned an MS in economics and accounting from Università degli Studi di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. Mr. Pucci has previously served on the Board of several successful biotech companies including Algeta ASA, until it was acquired by Bayer AG and Dyax Inc., until it was acquired by Shire Plc. Mr. Pucci currently serves as a board member of West Pharmaceuticals Services, Inc.